Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Engineered CAR-T Cells Show Promise Against Deadly Pediatric Brain Cancer

3d ago October 29, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

Scientists at UC San Francisco have developed engineered CAR-T cells that remain dormant until they reach the brain, effectively targeting and destroying diffuse midline glioma (DMG) in mice. This advancement in cancer treatment could have implications for pediatric healthcare in Iran, where cancer treatment resources are limited.

🔍 Quick Context Guide
💡 Bottom Line: The engineered CAR-T cells represent a significant step forward in the fight against a deadly childhood cancer, with potential global implications.

👥 Key Players

UC San Francisco MENTIONED
Research institution
"They are at the forefront of cancer research, which can influence treatment options available globally, including in Iran."
Pediatric oncologists MENTIONED
Medical professionals specializing in childhood cancers
"Their expertise is crucial in implementing new treatments and improving outcomes for children with cancer in Iran."

📰 What Happened

Scientists at UC San Francisco have developed CAR-T cells that remain dormant until they reach the brain, effectively targeting and destroying a lethal form of childhood brain cancer in mice. This breakthrough could lead to new treatment options for pediatric brain cancer patients.

  • The engineered CAR-T cells target diffuse midline glioma (DMG), a highly aggressive brain cancer in children.
  • The treatment showed lasting effects, as the CAR-T cells remained effective even after a subsequent introduction of cancer.

💡 Why It Matters

🇮🇷 For Iran: This research could provide new hope for pediatric cancer patients in Iran, where treatment options are often limited.
🌍 Regional: Advancements in cancer treatment could enhance healthcare capabilities in the region, potentially benefiting neighboring countries.
🌐 International: This development may attract international interest and investment in cancer research and treatment innovations.

📚 Background

Diffuse midline glioma is a particularly challenging cancer to treat due to its integration into healthy brain tissue. CAR-T cell therapy is an innovative approach that modifies a patient's immune cells to better target and destroy cancer cells.

CAR-T cell therapy Pediatric oncology
📡 Source: NEUTRAL
📊 Confidence: 70%
This source presents scientific findings and advancements without apparent bias, focusing on research outcomes.

Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells. In mice, these CAR-T cells were able to clear diffuse midline glioma (DMG), a lethal form of childhood brain cancer that integrates into healthy tissue. The cells also had staying power. When scientists introduced another round of cancer several weeks later, the cells were still able to fight.

🏷️ Entities Mentioned

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →